secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001753926-25-001228
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Vivani Medical reports positive Phase 1 data for NPM-115 implant and prioritizes semaglutide implant NPM-139
--------------------------------------------------------------------------------

- Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.
- LIBERATE-1 Phase 1 study of NPM-115 (exenatide implant) met primary safety and PK objectives; no serious adverse events.
- Preclinical data for NPM-139 (semaglutide implant) showed ~20% weight loss maintained over 231 days from a single implant.
- Vivani prioritizes NPM-139 for clinical development, with IND submission planned and clinical start expected in 2026.
- Semaglutide products (Ozempic, Wegovy, Rybelsus) generated over $29B in 2024 sales, supporting prioritization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625001228/0001753926-25-001228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625001228/vani-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer